Cargando…

Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration

The application of fluoropyrimidine-based neoadjuvant chemoradiotherapy (Fu-nCRT) of locally advanced rectal cancer (LARC) has become a common therapeutic regimen. In order to improve the efficacy and enable more patients to benefit from this treatment, an accumulation of studies have been carried o...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Fengpeng, Zhou, Chaoxi, Wu, Bingyuan, Zhang, Xiaoxiao, Wang, Kanghua, Wang, Jun, Xiao, Linlin, Wang, Guiying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739002/
https://www.ncbi.nlm.nih.gov/pubmed/33391438
http://dx.doi.org/10.7150/jca.48337
_version_ 1783623240933965824
author Wu, Fengpeng
Zhou, Chaoxi
Wu, Bingyuan
Zhang, Xiaoxiao
Wang, Kanghua
Wang, Jun
Xiao, Linlin
Wang, Guiying
author_facet Wu, Fengpeng
Zhou, Chaoxi
Wu, Bingyuan
Zhang, Xiaoxiao
Wang, Kanghua
Wang, Jun
Xiao, Linlin
Wang, Guiying
author_sort Wu, Fengpeng
collection PubMed
description The application of fluoropyrimidine-based neoadjuvant chemoradiotherapy (Fu-nCRT) of locally advanced rectal cancer (LARC) has become a common therapeutic regimen. In order to improve the efficacy and enable more patients to benefit from this treatment, an accumulation of studies have been carried out on the auxiliary use of other drugs with Fu-nCRT. However, due to specific challenges and the potential opportunities that coexist in this field, a more reasonable approach to the mode of treatment remains to be explored. In this review, we have summarized the results of the studies on the combination of Fu-nCRT with cytotoxic drugs, anti-tumor angiogenesis, and anti-EGFR agents, as well as the status of the application of immune checkpoint inhibitors in the neoadjuvant therapy of LARC patients.
format Online
Article
Text
id pubmed-7739002
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-77390022021-01-01 Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration Wu, Fengpeng Zhou, Chaoxi Wu, Bingyuan Zhang, Xiaoxiao Wang, Kanghua Wang, Jun Xiao, Linlin Wang, Guiying J Cancer Review The application of fluoropyrimidine-based neoadjuvant chemoradiotherapy (Fu-nCRT) of locally advanced rectal cancer (LARC) has become a common therapeutic regimen. In order to improve the efficacy and enable more patients to benefit from this treatment, an accumulation of studies have been carried out on the auxiliary use of other drugs with Fu-nCRT. However, due to specific challenges and the potential opportunities that coexist in this field, a more reasonable approach to the mode of treatment remains to be explored. In this review, we have summarized the results of the studies on the combination of Fu-nCRT with cytotoxic drugs, anti-tumor angiogenesis, and anti-EGFR agents, as well as the status of the application of immune checkpoint inhibitors in the neoadjuvant therapy of LARC patients. Ivyspring International Publisher 2021-01-01 /pmc/articles/PMC7739002/ /pubmed/33391438 http://dx.doi.org/10.7150/jca.48337 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Review
Wu, Fengpeng
Zhou, Chaoxi
Wu, Bingyuan
Zhang, Xiaoxiao
Wang, Kanghua
Wang, Jun
Xiao, Linlin
Wang, Guiying
Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration
title Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration
title_full Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration
title_fullStr Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration
title_full_unstemmed Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration
title_short Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration
title_sort adding adjuvants to fluoropyrimidine-based neoadjuvant chemoradiotherapy for locally advanced rectal cancer: an option worthy of serious consideration
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7739002/
https://www.ncbi.nlm.nih.gov/pubmed/33391438
http://dx.doi.org/10.7150/jca.48337
work_keys_str_mv AT wufengpeng addingadjuvantstofluoropyrimidinebasedneoadjuvantchemoradiotherapyforlocallyadvancedrectalcanceranoptionworthyofseriousconsideration
AT zhouchaoxi addingadjuvantstofluoropyrimidinebasedneoadjuvantchemoradiotherapyforlocallyadvancedrectalcanceranoptionworthyofseriousconsideration
AT wubingyuan addingadjuvantstofluoropyrimidinebasedneoadjuvantchemoradiotherapyforlocallyadvancedrectalcanceranoptionworthyofseriousconsideration
AT zhangxiaoxiao addingadjuvantstofluoropyrimidinebasedneoadjuvantchemoradiotherapyforlocallyadvancedrectalcanceranoptionworthyofseriousconsideration
AT wangkanghua addingadjuvantstofluoropyrimidinebasedneoadjuvantchemoradiotherapyforlocallyadvancedrectalcanceranoptionworthyofseriousconsideration
AT wangjun addingadjuvantstofluoropyrimidinebasedneoadjuvantchemoradiotherapyforlocallyadvancedrectalcanceranoptionworthyofseriousconsideration
AT xiaolinlin addingadjuvantstofluoropyrimidinebasedneoadjuvantchemoradiotherapyforlocallyadvancedrectalcanceranoptionworthyofseriousconsideration
AT wangguiying addingadjuvantstofluoropyrimidinebasedneoadjuvantchemoradiotherapyforlocallyadvancedrectalcanceranoptionworthyofseriousconsideration